University of Pittsburgh researchers have developed a novel set of quality control standards for selecting human corneal stromal stem cells (CSSCs) with optimal regenerative capabilities. This advancement aims to improve the effectiveness of stem cell therapy for corneal scarring, a leading cause of vision loss worldwide. By identifying the most relevant indicators of CSSC quality, this technology ensures the selection of cells with high healing potential, paving the way for more successful clinical trials and treatments.